Quick Search 
Drugs of Today
Register or sign in

  
 
  
Drugs Today 2020, 56(5): 329
ISSN 1699-3993
Copyright 2020 Clarivate Analytics
CCC: 1699-3993
DOI: 10.1358/dot.2020.56.5.3127027
 
 
Enfortumab vedotin to treat urothelial carcinoma
Hanna, K.S.
 
 
The antibody-drug conjugate enfortumab vedotin is a fully humanized monoclonal antibody targeting Nectin-4 linked to a microtubule-disrupting agent, monomethyl auristatin E, via a protease-cleavable maleimidocaproyl valine-citrulline linker. In this article, we provide a comprehensive review of the preclinical and clinical activity of enfortumab vedotin, which has been recently approved in the U.S. for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who have previously received a programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) inhibitor as well as platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. Enfortumab vedotin is the first antibody-drug conjugate approved for patients with urothelial carcinoma.


Full Text: PDF 
 
  



© Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy